Alexion Win Thwarts Roche’s EU Fast-Track Hopes

 
• By Neena Brizmohun

Roche hopes that its investigational drug satralizumab for neuromyelitis optica spectrum disorder will win EU approval in the second half of 2020.

Hourglass
EU filing for satralizumab has reverted to the standard review timeline • Source: PS141712

More from Europe

More from Geography